Vernal Appoints Jim Petrilla as CEO and Board Director
New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver Innovative Therapies Faster. COLCHESTER, Vt., October 31, 2024 /BUSINESS WIRE/ — Vernal…
Vernal Launches Integrated Analytical & QC Services—Facilitating Faster mRNA Medicine Development
COLCHESTER, Vt., October 9, 2024 — Vernal Biosciences, a leader in mRNA and lipid nanoparticle (LNP) manufacturing, announces that its analytical and quality control (QC) services for…
Vernal Showcases Innovations at mRNA Health Conference
Experience the incredible insights Vernal has to offer regarding its cutting-edge capping technology and the exceptional quality of our mRNA. We will be showcasing this groundbreaking information…
Vernal Biosciences Announces Partnership with REPROCELL
Vernal is excited to announce its new partnership with REPROCELL, furthering our mission to democratize access to mRNA, a life-changing technology, around the world. REPROCELL is a trusted leader…
Vernal featured on Businesswire
Find our latest article on Businesswire here: Vermont-based CDMO, Vernal Biosciences Announces an Additional $20MM in Funding to Expand GMP mRNA and LNP Manufacturing Click the orange…
Vermont Celebrates Vernal Success in a VT Digger Article
Every success has an origin story. Check out this new VT Digger article on how CEO Christian Cobaugh, Ph.D. founded Vernal Biosciences, and what makes Vernal uniquely…